product name Andrographolide
References: J Immunol. 2004 Sep 15;173(6):4207-17.
350.45
Formula
C20H30O5
CAS No.
5508-58-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 70 mg/mL (199.7 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Andrographolide was found to suppress the expression of inducible nitric oxide synthase in a concentration-dependent manner. In the andrographolide-treated group, a reduction of Akt, c-Jun N-terminal kinase and p65 phosphorylation was observed. Andrographolide also caused a decrease in Bcl-2/NF-κb expression and a dose-dependent increase in the expression of Cleaved-Caspase3/Bax protein. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Rats were dosed with andrographolide intragastrically for 5 consecutive days in a hepatoprotection study. Results indicated that andrographolide could up-regulate glutamate cysteine ligase catalytic and modifier subunits, heme oxygenase-1, superoxide dismutase-1, glutathione S-transferase protein and mRNA expression in the heart, liver, and kidney. |
| Animal model | |
| Formulation & Dosage | |
| References | Dis Esophagus. 2016 Jan;29(1):54-61; Toxicol Appl Pharmacol. 2014 Oct 1;280(1):1-9. |
